DK1363676T3 - Fremgangsmåde til forögelse af administration af en terapeutisk nukleinsyre - Google Patents
Fremgangsmåde til forögelse af administration af en terapeutisk nukleinsyreInfo
- Publication number
- DK1363676T3 DK1363676T3 DK02704215T DK02704215T DK1363676T3 DK 1363676 T3 DK1363676 T3 DK 1363676T3 DK 02704215 T DK02704215 T DK 02704215T DK 02704215 T DK02704215 T DK 02704215T DK 1363676 T3 DK1363676 T3 DK 1363676T3
- Authority
- DK
- Denmark
- Prior art keywords
- nucleic acid
- therapeutic nucleic
- enhancing
- administration
- host
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26341601P | 2001-01-22 | 2001-01-22 | |
| PCT/US2002/001797 WO2002056918A2 (en) | 2001-01-22 | 2002-01-22 | Method of enhancing delivery of a therapeutic nucleic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1363676T3 true DK1363676T3 (da) | 2007-07-23 |
Family
ID=23001688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02704215T DK1363676T3 (da) | 2001-01-22 | 2002-01-22 | Fremgangsmåde til forögelse af administration af en terapeutisk nukleinsyre |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7534424B2 (es) |
| EP (1) | EP1363676B1 (es) |
| JP (1) | JP2005502585A (es) |
| AT (1) | ATE357935T1 (es) |
| AU (1) | AU2002237910B2 (es) |
| CA (1) | CA2435443A1 (es) |
| CY (1) | CY1106676T1 (es) |
| DE (1) | DE60219142T2 (es) |
| DK (1) | DK1363676T3 (es) |
| ES (1) | ES2283524T3 (es) |
| NZ (1) | NZ527645A (es) |
| PT (1) | PT1363676E (es) |
| WO (1) | WO2002056918A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696423B1 (en) * | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| JP4736413B2 (ja) * | 2004-12-14 | 2011-07-27 | 富士ゼロックス株式会社 | 生体分子保持物及び生体分子の保存方法 |
| JPWO2011074564A1 (ja) * | 2009-12-15 | 2013-04-25 | タカラバイオ株式会社 | アデノウイルスベクターの製造方法 |
| US20140141065A1 (en) * | 2012-11-19 | 2014-05-22 | Discovery Genomics, Inc. | Method to achieve extended expression of dna infused into liver |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) * | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4797368A (en) * | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5262564A (en) * | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| DE19525900C1 (de) * | 1995-07-15 | 1996-12-12 | Max Planck Gesellschaft | Leberspezifischer Adenovirus-Expressionsvektor |
| US6696423B1 (en) * | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| DE69833264T2 (de) * | 1997-08-29 | 2006-09-28 | Biogen Idec Ma Inc., Cambridge | Verfahren und zusammensetzungen für die krebstherapie unter verwendung von interferon-beta codierenden genen |
| US20010031741A1 (en) * | 2000-02-17 | 2001-10-18 | Robin Ziegler | Methods for treatment of lysosomal storage diseases |
-
2002
- 2002-01-22 AT AT02704215T patent/ATE357935T1/de not_active IP Right Cessation
- 2002-01-22 CA CA002435443A patent/CA2435443A1/en not_active Abandoned
- 2002-01-22 AU AU2002237910A patent/AU2002237910B2/en not_active Ceased
- 2002-01-22 WO PCT/US2002/001797 patent/WO2002056918A2/en active IP Right Grant
- 2002-01-22 DK DK02704215T patent/DK1363676T3/da active
- 2002-01-22 DE DE60219142T patent/DE60219142T2/de not_active Expired - Fee Related
- 2002-01-22 ES ES02704215T patent/ES2283524T3/es not_active Expired - Lifetime
- 2002-01-22 EP EP02704215A patent/EP1363676B1/en not_active Expired - Lifetime
- 2002-01-22 JP JP2002557425A patent/JP2005502585A/ja active Pending
- 2002-01-22 NZ NZ527645A patent/NZ527645A/en unknown
- 2002-01-22 PT PT02704215T patent/PT1363676E/pt unknown
-
2003
- 2003-07-11 US US10/618,299 patent/US7534424B2/en not_active Expired - Lifetime
-
2007
- 2007-06-25 CY CY20071100841T patent/CY1106676T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60219142T2 (de) | 2007-12-13 |
| CY1106676T1 (el) | 2012-05-23 |
| PT1363676E (pt) | 2007-06-22 |
| AU2002237910C1 (en) | 2002-07-30 |
| WO2002056918B1 (en) | 2004-04-08 |
| ATE357935T1 (de) | 2007-04-15 |
| US20040086486A1 (en) | 2004-05-06 |
| CA2435443A1 (en) | 2002-07-25 |
| DE60219142D1 (de) | 2007-05-10 |
| US7534424B2 (en) | 2009-05-19 |
| EP1363676B1 (en) | 2007-03-28 |
| WO2002056918A3 (en) | 2002-11-14 |
| AU2002237910B2 (en) | 2007-01-25 |
| ES2283524T3 (es) | 2007-11-01 |
| JP2005502585A (ja) | 2005-01-27 |
| WO2002056918A2 (en) | 2002-07-25 |
| EP1363676A2 (en) | 2003-11-26 |
| NZ527645A (en) | 2008-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL371736A1 (en) | Method for administering glp-1 molecules | |
| NO20065860L (no) | Stabiliserte flytende interferonformuleringer | |
| TNSN08064A1 (en) | Albumin fusion proteins | |
| HUP0401534A2 (hu) | Módosított humán IX. faktor | |
| HK1065562A1 (en) | Methods and compositions for rnai mediated inhibition of gene expression in mammals | |
| DE50211110D1 (de) | INJEKTIONSGERÄT FÜR mRNA APPLIKATION | |
| WO2002006316A3 (en) | Alpha-msh related compounds and methods of use | |
| ATE510011T1 (de) | Neue pilzproteine und diese codierende nukleinsäuren | |
| GB2398220A (en) | Automated foot bath apparatus and method | |
| DK1163349T3 (da) | Medicinske præparater til behandling af alfa-galactosidase A-mangel | |
| MXPA05013340A (es) | Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento. | |
| WO2005084296A3 (en) | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3 | |
| WO2003028757A1 (fr) | Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes | |
| ATE374251T1 (de) | Zusammensetzungen zur gentherapie von diabetes | |
| DK1290011T3 (da) | Melphalan-derivater og deres anvendelse som cancer-kemoterapeutiske lægemidler | |
| BR0009472A (pt) | Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas | |
| MY157947A (en) | Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity | |
| NO20073914L (no) | Biologisk aktive peptider | |
| ATE371031T1 (de) | Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs | |
| DK1363676T3 (da) | Fremgangsmåde til forögelse af administration af en terapeutisk nukleinsyre | |
| WO2005042566A3 (en) | Antiangiogenicpeptides for treating or preventing endometriosis | |
| DE60317565D1 (de) | Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden | |
| WO2003106640A3 (en) | CELL TARGETING METHODS AND COMPOSITIONS | |
| EA200500764A1 (ru) | Фармацевтические композиции и лекарственные формы для трансбуккальной и сублингвальной доставки тизанидина и способы введения тизанидина сублингвально или трансбуккально | |
| DK1268522T3 (da) | LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler |